Glaucoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Glaucoma is a chronic and progressive ocular disease that results in visual field loss due to damage to the optic nerve. The optic nerve is responsible for transmitting visual information from the retina to the brain, and damage to this nerve can cause irreversible vision loss. It can manifest in different forms, including primary (open-angle, normal-tension, angle-closure, congenital glaucoma) and secondary (neovascular, pigmentary, exfoliation, and uveitic glaucoma). The main risk factor for the disease is increased intraocular pressure caused by abnormalities in the eye’s drainage system, leading to fluid buildup that damages the optic nerve. Diagnosis of glaucoma requires various tests, including visual acuity tests, pupil dilation, visual field tests, tonometry, optic nerve imaging, gonioscopy, and pachymetry. The prognosis depends on the stage at which it is detected and requires aggressive treatment. It implies a worse long-term prognosis when the optic nerve has already suffered permanent damage and the diagnosis comes late.
• More than 3 million individuals in the USA live with glaucoma, of which 2.7 million are aged 40 and above, affected mainly by one-angle glaucoma.

Thelansis’s “Glaucoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Glaucoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Glaucoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Glaucoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Glaucoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033